



INDUSTRIAL BIOTECHNOLOGY IN AUSTRIA

INDUSTRIAL BIOTECHNOLOGY IN AUSTRIA¹

INTRODUCTION	3
I. RESEARCH AND INNOVATION	4
A. Public research funding	4
B. Pilot and demonstration plants	4
i. pilot plants	4
ii. demonstration plants	5
II. POLICY	6
A. Policies and regulations	6
B. Public procurement	6
C. Standardisation, labelling and certification	6
D. Access to finance	6
E. Communication	6

Released in February 2009

¹ Please send your contributions and modifications to a.peeters@europabio.org

INDUSTRIAL BIOTECHNOLOGY IN AUSTRIA

INTRODUCTION

Austrian biotechnology actors are mainly involved in healthcare biotechnology. The size of the biotechnology industry is considerably smaller than in other western European countries due to the lack of leading multinational corporations in the chemical-pharmaceutical sector. Recently, several industrial stakeholders have launched the Austrian Centre of Industrial Biotechnology with the aim of supporting white biotech research in the country.

I. RESEARCH AND INNOVATION

Modern industrial biotechnology is a relatively new discipline, with major areas of knowledge still to be explored. Public support to research as well as the establishment of pilot and demonstration facilities to scale-up individual processes will therefore help in the development of a European bio-based economy.

A. Public research funding

The Austrian Centre of Industrial Biotechnology² regroups several research actors active in the industrial biotech sector in Austria. It plans to make the development of bioprocesses more transparent, predictable and thus faster, calculable and cheaper.

The Research Centre Applied Biocatalysis³ is involved in the Austrian Centre of Industrial Biotechnology. It aims to focus the expertise of all partners to form a Research Centre for Applied Biocatalysis with sustained international and national competitiveness that forms an attractive platform for applied biocatalysis.

B. Pilot and demonstration plants

No information

i. pilot plants

a) **Open to all**

b) **Partly restricted**

VogelBusch, Single Column SMB Chromatography, Vienna	
General, products, feedstocks	Services offer by the company include technology, engineering and contracting of process plants. Target markets are the biotechnology industry, including pharmaceuticals, chemistry and foodstuffs.
Services	<ul style="list-style-type: none">– Adsorbent volume: 95 liters 25 gal (US)– Inner column diameter: 110 mm 4.3 in– Adsorbent size: 200 – 400 µm– MOC: stainless steel, industrial design– Inline-online analysis: density meter, refractometer, polarimeter– Typical feed flow: 130 kg DMS per day (e.g. HFS)
Financing	
Contact	vienna@vogelbusch.com / www.vogelbusch-biocommodities.com

c) **Restricted**

Lactosan Biotech, Kapfenberg	
General, products, feedstocks	Lactosan manufactures products based on living lactic acid bacteria. The core business is the production and formulation of probiotics in animal feed and the manufacture of starter cultures for silage as feed and for biogas production.
Services	Large pilot fermenter: <ul style="list-style-type: none">– Total volume 300 l

² <http://www.a-b.tugraz.at/ACIB/>

³ http://www.a-b.tugraz.at/index_en.htm

	<ul style="list-style-type: none"> – Working volume anaerob 250 l – Working volume aerob 200 l <p>Medium pilot fermenter:</p> <ul style="list-style-type: none"> – Total volume 200 l – Working volume anaerob 180 l – Working volume aerob 150 l <p>Small pilot fermenter</p> <ul style="list-style-type: none"> – Total volume 16 l – Working volume anaerob 13 l – Working volume aerob 10 l
Financing	No information
Contact	info@lactosan.at / http://www.lactosan.at

ii. demonstration plants

- a) **Open to all**
- b) **Partly restricted**
- c) **Restricted**

II. POLICY

Public authorities can promote the quick take-up of industrial biotechnology innovations by implementing a number of “instruments” or policy initiatives. This can be the improvement of the regulatory framework; the integration of specification for bio-based products in public procurement; the establishment of standardisation, labelling and certification schemes to overcome perceived uncertainty about product properties and weak market transparency; the development of financial instruments and supports to increase investments into research, technology development and innovation as well as the elaboration of communication and information campaign to communicate the benefits of bio-based products to users.

A. Policies and regulations

No information

B. Public procurement

No information

C. Standardisation, labelling and certification

No information

D. Access to finance

No information

E. Communication

No information